ProKidney Corp. (PROK) shares surged 496.87 percent to $3.62 on Tuesday after the company announced positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel, a potential treatment for chronic kidney disease in patients with diabetes.
Shares opened at $1.27 and traded between $1.02 and $4.45 on the day, with volume spiking to 292.2 million shares, far above the 1.1 million average on the Nasdaq. The stock now trades near its 52-week high of $4.45, after closing at just $0.61 the previous session.
The therapy, which has FDA RMAT designation, showed statistically significant improvements in kidney function, bolstering confidence in its ongoing Phase 3 PROACT 1 trial. ProKidney plans to submit the full REGEN-007 data for presentation at the 2025 ASN Kidney Week and is preparing for an upcoming FDA Type B meeting regarding accelerated approval pathways.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.